Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: Little is known about the longitudinal patterns of buprenorphine adherence among pregnant women with opioid use disorder, especially when late initiation, nonadherence, or early discontinuation of buprenorphine during pregnancy may increase the risk of adverse outcomes. We aimed to identify distinct trajectories of buprenorphine use during pregnancy, and factors associated with these trajectories in Medicaid‐enrolled pregnant women. Methods: A retrospective cohort study included 2361 Pennsylvania Medicaid enrollees aged 15 to 46 having buprenorphine therapy during pregnancy and a live birth between 2008 and 2015. We used group‐based trajectory models to identify buprenorphine use patterns in the 40 weeks prior to delivery and 12 weeks postdelivery. Multivariable multinomial logistic regression models were used to identify factors associated with specific trajectories. Results: Six distinct trajectories were identified. Four groups initiated buprenorphine during the first trimester of the pregnancy (early initiators): 31.6% with persistently high adherence, 15.1% with moderate‐to‐high adherence, 10.5% with declining adherence, and 16.7% with early discontinuation. Two groups did not initiate buprenorphine until midsecond or third trimester (late initiators): 13.5% had moderate‐to‐high adherence and 12.6% had low‐to‐moderate adherence. Factors significantly associated with late initiation and discontinuation were younger age, non‐white race, residents of rural counties, fewer outpatient visits, more frequent emergency department visits and hospitalizations, and lower buprenorphine daily dose. Conclusions: Six buprenorphine treatment trajectories during pregnancy were identified in this population‐based Medicaid cohort, with 25% of women initiating buprenorphine late during pregnancy. Understanding trajectories of buprenorphine use and factors associated with discontinuation/nonadherence may guide integration of behavioral treatment with obstetrical/gynecological care to improve buprenorphine treatment during pregnancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Group-Based Modeling of Development
NAGIN, D. (2005) · doi:10.4159/9780674041318 · Cited by 4,164
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Opioid Abuse and Dependence during Pregnancy: Temporal Trends and Obstetrical Outcomes
Maeda, A., Bateman, B. T., Clancy, C. R., Creanga, A. A., & Leffert, L. R. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000472 · Cited by 317 · cited 1×
“PregnantwomenwithOUDhave an increased risk of adverse maternal, obstetric, and neonatal outcomes (eg, preterm birth, fetal growth restriction).(2,3) Opioid agonist therapy has been shown to reduce illicit drug use and the risk of infection and improve adherence to prenatal care, maternal nutrition, and infant birth we…”
BackgroundPatterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program
Gordon, A. J., Lo-Ciganic, W.-H., Cochran, G., Gellad, W. F., Cathers, T., Kelley, D., & Donohue, J. M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000164 · Cited by 76 · cited 1×
“Finally, we measured whether patients received any behavioral counseling as proxy of quality of care for their OUD during the pregnancy.(32) We also examined whether women received any drug urine tests during pregnancy although false positive results from urine drug testing raise concerns regarding negative consequenc…”
MethodSelf-citation
Cited by
Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder
Schiff, D. M., Nielsen, T. C., Hoeppner, B. B., Terplan, M., Hadland, S. E., Bernson, D., Greenfield, S. F., Bernstein, J., Bharel, M., Reddy, J., et al. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.04.210 · Cited by 69
Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?
Dunphy, C., Peterson, C., Zhang, K., & Jones, C. M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108784 · Cited by 41
Shen, Y., Lo-Ciganic, W.-H., Segal, R., & Goodin, A. J. (2021) · Journal of Psychosomatic Obstetrics & Gynecology · doi:10.1080/0167482x.2020.1727882 · Cited by 38
“Most studies used convenience samples [6,10,12,19,20,30–36] or focused on a specific population such as Medicaid recipients [37].”
BackgroundSelf-citationNguemeni Tiako, M. J., Friedman, A., Culhane, J., South, E., & Meisel, Z. F. (2021) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000004307 · Cited by 21
Metadata
- Authors
- Lo‐Ciganic, W., Donohue, J. M., Kim, J. Y., Krans, E. E., Jones, B. L., Kelley, D., James, A. E., & Jarlenski, M. P.
- Venue
- Pharmacoepidemiology and Drug Safety
- Publisher
- Wiley
- Published
- 2018-09-07
- Volume
- 28
- Issue
- 1
- Pages
- 80-89
- ISSN
- 1053-8569 (ISSN-L)
- 1099-1557
- OpenAlex
- W2891514988
- Cited by
- 55
- References
- 4
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.